Maxim Group Maintains Buy on Actinium Pharma, Raises Price Target to $30
Portfolio Pulse from Benzinga Newsdesk
Maxim Group analyst Jason McCarthy maintains a Buy rating on Actinium Pharma (ATNM) and raises the price target from $20 to $30.
March 19, 2024 | 4:59 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Maxim Group analyst Jason McCarthy reaffirms a Buy rating on Actinium Pharma and increases the price target from $20 to $30.
The increase in price target by a reputable analyst like Jason McCarthy suggests a strong confidence in Actinium Pharma's future performance. This endorsement is likely to positively influence investor sentiment and potentially drive up the stock price in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100